Literature DB >> 2521973

Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure.

T Tsutamoto1, K Bito, M Kinoshita.   

Abstract

To evaluate the relationship between plasma atrial natriuretic polypeptide (ANP), hemodynamic parameters, and plasma catecholamines and, in addition, to determine whether circulating ANP is metabolized in the pulmonary circulation, plasma concentrations of ANP were determined in 40 patients with chronic left-sided heart failure. After at least 30 minutes of bed rest with the patient in the supine position, blood samples were drawn simultaneously from both the main pulmonary artery (mPA) and the ascending aorta (Ao) before administration of contrast medium. The plasma ANP concentrations significantly decreased from the mPA to the Ao (135.3 +/- 18.1 pg/ml vs 127.4 +/- 19.4 pg/ml; mean +/- SEM, p less than 0.05). The plasma ANP level in the mPA correlated with the plasma norepinephrine level in the Ao (r = 0.71, p less than 0.01), right atrial pressure (r = 0.34, p less than 0.05), mean pulmonary capillary wedge pressure (r = 0.829, p less than 0.001), and left ventricular end-diastolic pressure (LVEDP) (r = 0.88, p less than 0.001). Of the various hemodynamic parameters and plasma catecholamine concentrations in the Ao, only LVEDP was found to be an independent and significant predictor of plasma ANP levels in the mPA. These results indicate that ANP released from the heart is regulated mainly by preload (LVEDP) in cases of left-sided heart failure and that circulating ANP is metabolized in the pulmonary circulation. In conclusion, the plasma ANP concentration may be a useful noninvasive index of LVEDP in patients with chronic left-sided heart failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521973     DOI: 10.1016/0002-8703(89)90734-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  5 in total

1.  Level Of Natriuretic Peptide Determines Outcome In Atrial Fibrillation.

Authors:  Qi-Xian Zeng; Ming-Fen Wei; Wei Zhang; Yun Zhang; Jing-Quan Zhong
Journal:  J Atr Fibrillation       Date:  2010-01-01

2.  Atrial natriuretic peptide concentrations in children with pulmonary hypertension: correlation with hemodynamic measurements.

Authors:  F S Tunaoglu; F R Olgunturk; N Gokcora; C Turkyilmaz; F Gurbuz
Journal:  Pediatr Cardiol       Date:  1994 Nov-Dec       Impact factor: 1.655

3.  Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

Authors:  T Omland; V V Bonarjee; D W Nilsen; J A Sundsfjord; R T Lie; G Thibault; K Dickstein
Journal:  Br Heart J       Date:  1993-11

4.  Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure.

Authors:  C Haug; A Metzele; J Steffgen; M Kochs; V Hombach; A Grünert
Journal:  Clin Investig       Date:  1994-06

5.  Recombinant Atrial Natriuretic Peptide Prevents Aberrant Ca2+ Leakage through the Ryanodine Receptor by Suppressing Mitochondrial Reactive Oxygen Species Production Induced by Isoproterenol in Failing Cardiomyocytes.

Authors:  Wakako Murakami; Shigeki Kobayashi; Takehisa Susa; Takuma Nanno; Hironori Ishiguchi; Takeki Myoren; Shigehiko Nishimura; Takayoshi Kato; Akihiro Hino; Tetsuro Oda; Shinichi Okuda; Takeshi Yamamoto; Masafumi Yano
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.